PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that Tim M. Mayleben, Esperion's president and chief executive
officer, will present at the BioCentury Newsmakers in the Biotech
Industry Conference in New York. Mr. Mayleben's presentation will take
place on Friday, September 27 at 2:00 ET at the Millennium Broadway
Hotel and Conference Center.
To hear the live audio webcast and view the slides of the Esperion
presentation, please visit (http://www.visualwebcaster.com/event.asp?id=95799).
A replay of the webcast will be available on the company's website for
90 days following the live event.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower levels of LDL-C
and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and expects to initiate a
robust Phase 2b clinical program in the fourth quarter of 2013. For more
information, please visit www.esperion.com.
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media